HOOK News and Press, HOOKIPA Pharma Inc. From 06/03/22

Hookipa Pharma (NASDAQ:HOOK) on Friday announced positive preclinical data from arenaviral therapeutic vaccines that are being studied as a component of a potential functional curative regimen for HIV.  (HOOK) up ~2% before the bell. The studies are being done in coll...

Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting ...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase ...

HOOKIPA Pharma press release (NASDAQ:HOOK): Q1 GAAP EPS of -$0.40 misses by $0.19. Revenue of $1.44M (-72.8% Y/Y) misses by $13.09M. For further details see: HOOKIPA Pharma GAAP EPS of -$0.40 misses by $0.19, revenue of $1.44M misses by $13.09M

HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizumab in second half of 2022 Q1 capital raise and Gilead collaboration funding generated a strong cash position of $142 million NEW YORK and VIENNA, Austria, May 16, 2022 (GLOBE N...

NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial ...

HOOKIPA Pharma (NASDAQ:HOOK) promoted Christine D. Baker to COO, effective immediately; Christine joined HOOKIPA in August 2019 as Chief Business Officer and has played a critical role in securing several strategic business collaborations for HOOKIPA's novel arenavira...

NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Opera...

NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Boar...